The combination therapy of nivolumab (NIVO) and cabozantinib (CABO) with or without ipilimumab (IPI) demonstrates activity in advanced hepatocellular carcinoma (aHCC), according to the CheckMate 040* study presented at ASCO GI 2020.
Not only does washing away free tumour cells in the peritoneum with extensive intraoperative peritoneal lavage (EIPL) during gastrectomy confer no survival benefit nor prevent disease recurrence compared with surgery alone, it may come with an increased risk of side effects, according to the phase III EXPEL* study presented at GICS 2020.
In addition to survival benefit, the BEACON CRC trial has now shown that a targeted drug combination of encorafenib plus cetuximab with or without binimetinib led to longer maintenance of quality of life (QoL) for patients with BRAF V600E metastatic colorectal cancer (mCRC) compared with standard chemotherapy.
Primary tumour resection (PTR) prior to a chemotherapy regimen does not improve survival outcomes in patients with asymptomatic unresectable stage IV colorectal cancer (CRC), according to the phase III JCOG1007* trial.
Neoadjuvant chemotherapy with S-1 and oxaliplatin (SOX) may be a suitable treatment measure for patients with advanced gastric or esophagogastric junction adenocarcinoma, according to the RESONANCE* trial presented at ASCO GI 2020.
Adding pegilodecakin, a pegylated form of interleukin-10 (IL-10), to second-line FOLFOX chemotherapy does not significantly improve overall survival (OS) or other outcomes in patients with advanced pancreatic ductal adenocarcinoma (PDAC) as compared with FOLFOX alone, results of the phase III SEQUOIA trial have shown.
The combination of the PD-L1* inhibitor atezolizumab and the VEGF** inhibitor bevacizumab generated substantial and consistent benefits in terms of quality of life (QoL) compared with standard-of-care sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, according to the patient-reported outcomes (PROs) from the IMbrave150*** trial presented at ASCO GI 2020.
The TAPUR study – the first clinical trial conducted by the American Society of Clinical Oncology (ASCO) – may help identify new biomarker-based therapies for patients with heavily-pretreated colorectal cancer (CRC) who have HER2-positive or BRAFV600E-mutated tumours or a high tumour mutation burden (TMB) and have no standard treatment options.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
Drawing from experience as a key investigator in landmark
clinical trials (including PALOMA, MONALEESA and
MONARCH), and his clinical experience with
CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his
insights into the current evidence of using CDK4/6 inhibitors
to treat HR+/HER2- ABC.
Pembrolizumab monotherapy improves overall
survival (OS) and cancer control compared with platinum-based chemotherapy in
patients with untreated locally advanced or metastatic programmed death-ligand
1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11
or KEAP1 mutation status, according to results of the phase III